A round of Series D financing has brought in $13 million for Boston-based clinical-stage firm NeoSync. The proceeds will be used to fund a registration study of the company's NeoSync-EEG Synchronized TMS, or NEST, technology involving patients with treatment-resistant depression, as well as to prepare for the technology's commercial launch.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.